- Data reinforce the potential clinical
utility of combination therapy -
VANCOUVER, Feb. 21, 2018 /CNW/ - Sierra Oncology, Inc.
(Nasdaq: SRRA), a clinical stage drug development company focused
on advancing next generation DNA Damage Response (DDR) therapeutics
for the treatment of patients with cancer, today announced it has
been accepted to present preclinical data demonstrating that its
Chk1 inhibitor, SRA737, synergizes with niraparib, a poly
ADP-ribose inhibitor (PARPi), in a poster at the American
Association of Cancer Research (AACR) Annual Meeting 2018 being
held in Chicago, Illinois from
April 14-18.
"There is a strong biological rationale for synergy between
SRA737 and PARP inhibition, which is further validated by these
data. Notably, this combination was effective in homologous repair
proficient tumor cell lines where PARP inhibitors are substantially
less active in the clinical setting," said Dr. Christian Hassig, Chief Scientific Officer of
Sierra Oncology. "Sierra is designing a potential clinical study to
evaluate SRA737 in combination with a PARP inhibitor, including
evaluation in comparable patient populations."
Poster Title: The Chk1 inhibitor, SRA737, synergizes with
niraparib to kill cancer cells via multiple cell death pathways
Session Category: Experimental and Molecular
Therapeutics
Session Title: Cell Cycle, Drug Resistance, and
Combinations
Session Date and Time: Monday Apr 16,
2018 8:00 AM - 12:00 PM
Location: McCormick Place South, Exhibit Hall A, Poster
Section 37
Poster Board Number: 11
Permanent Abstract Number: 1853
The Poster will be available April 16,
2018 on the company's website at www.sierraoncology.com.
About Sierra Oncology
Sierra Oncology is a clinical
stage drug development company advancing next generation DNA Damage
Response (DDR) therapeutics for the treatment of patients with
cancer. Our lead drug candidate, SRA737, is a potent, highly
selective, orally bioavailable small molecule inhibitor of
Checkpoint kinase 1 (Chk1), currently being investigated in two
Phase 1 clinical trials in patients with advanced cancer. Sierra
Oncology is also advancing SRA141, a potent, selective, orally
bioavailable small molecule inhibitor of Cell division cycle 7
kinase (Cdc7) undergoing preclinical development. Cdc7 is a key
regulator of DNA replication and is involved in the DDR network,
making it a compelling emerging target for the potential treatment
of a broad range of tumor types. For more information, please visit
www.sierraoncology.com.
Cautionary Note on Forward-Looking Statements
This
press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements regarding Sierra Oncology's expectations from current
data, anticipated clinical development and potential benefits of
Sierra Oncology's product candidates. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. These statements are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described in the
forward-looking statements. Such forward-looking statements are
subject to risks and uncertainties, including, among others, the
risk that Sierra Oncology may be unable to successfully develop and
commercialize product candidates, SRA737 and SRA141 are at early
stages of development and may not demonstrate safety and efficacy
or otherwise produce positive results, Sierra Oncology may
experience delays in the preclinical and anticipated clinical
development of SRA737 or SRA141, Sierra Oncology may be unable to
acquire additional assets to build a pipeline of additional product
candidates, Sierra Oncology's third-party manufacturers may cause
its supply of materials to become limited or interrupted or fail to
be of satisfactory quantity or quality, Sierra Oncology's cash
resources may be insufficient to fund its current operating plans
and it may be unable to raise additional capital when needed,
Sierra Oncology may be unable to obtain and enforce intellectual
property protection for its technologies and product candidates and
the other factors described under the heading "Risk Factors" set
forth in Sierra Oncology's filings with the Securities and Exchange
Commission from time to time. Sierra Oncology undertakes no
obligation to update the forward-looking statements contained
herein or to reflect events or circumstances occurring after the
date hereof, other than as may be required by applicable law.
SOURCE Sierra Oncology